Investigational Drug Information for BIIB104
✉ Email this page to a colleague
What is the development status for investigational drug BIIB104?
BIIB104 is an investigational drug.
There have been 5 clinical trials for BIIB104.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 15th 2018.
The most common disease conditions in clinical trials are Schizophrenia, Cognitive Dysfunction, and [disabled in preview]. The leading clinical trial sponsors are Biogen and [disabled in preview].
There are forty-three US patents protecting this investigational drug and four hundred and eighteen international patents.
Summary for BIIB104
| US Patents | 43 |
| International Patents | 418 |
| US Patent Applications | 105 |
| WIPO Patent Applications | 18 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 1 (2018-11-15) |
| Vendors | 20 |
Recent Clinical Trials for BIIB104
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants | Biogen | Phase 1 |
| A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants | Biogen | Phase 1 |
| A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants | Biogen | Phase 1 |
Clinical Trial Summary for BIIB104
Top disease conditions for BIIB104
Top clinical trial sponsors for BIIB104
US Patents for BIIB104
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BIIB104 | ⤷ Sign Up | 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| BIIB104 | ⤷ Sign Up | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| BIIB104 | ⤷ Sign Up | Imidazopyridazine compounds | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| BIIB104 | ⤷ Sign Up | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiaz- in-8a(8H)-YL)-1,3-thiazol-4-YL] amides | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| BIIB104 | ⤷ Sign Up | Pyrazolopyrimidine compounds | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| BIIB104 | ⤷ Sign Up | N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a- (8H)-YL)-thiazol-4-YL) amides | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| BIIB104 | ⤷ Sign Up | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BIIB104
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BIIB104 | Argentina | AR099997 | 2034-04-10 | ⤷ Sign Up |
| BIIB104 | Australia | AU2015245260 | 2034-04-10 | ⤷ Sign Up |
| BIIB104 | Canada | CA2944971 | 2034-04-10 | ⤷ Sign Up |
| BIIB104 | Chile | CL2016002510 | 2034-04-10 | ⤷ Sign Up |
| BIIB104 | China | CN106459088 | 2034-04-10 | ⤷ Sign Up |
| BIIB104 | Costa Rica | CR20160455 | 2034-04-10 | ⤷ Sign Up |
| BIIB104 | Cuba | CU20160151 | 2034-04-10 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
